Literature for PT-100

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2019
1. de Vasconcelos,N.M., Vliegen,G., Goncalves,A., De Hert,E., Martin-Perez,R., Van Opdenbosch,N., Jallapally,A., Geiss-Friedlander,R., Lambeir,A.M., Augustyns,K., Van der Veken,P., De Meester,I. and Lamkanfi,M.
   DPP8/DPP9 inhibition elicits canonical Nlrp1b inflammasome hallmarks in murine macrophages
   Life Sci Alliance2, PubMed  Europe PubMed DOI  I
2017
2. Okondo,M.C., Johnson,D.C., Sridharan,R., Go,E.B., Chui,A.J., Wang,M.S., Poplawski,S.E., Wu,W., Liu,Y., Lai,J.H., Sanford,D.G., Arciprete,M.O., Golub,T.R., Bachovchin,W.W. and Bachovchin,D.A.
   DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis
   Nat Chem Biol13, 46-53. PubMed  Europe PubMed DOI  I
3. Wu,X., Wang,Y., Xu,J., Luo,T., Deng,J. and Hu,Y.
   MM-BMSCs induce naive CD4+ T lymphocytes dysfunction through fibroblast activation protein alpha
   Oncotarget8, 52614-52628. PubMed  Europe PubMed DOI  I
2004
4. [YEAR:1-8-2004]Adams,S., Miller,G.T., Jesson,M.I., Watanabe,T., Jones,B. and Wallner,B.P.
   PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism
   Cancer Res64, 5471-5480. PubMed  Europe PubMed DOI  I
5. McIntyre,J.A. and Castaner,J.
   Talabostat. Oncolytic, hematopoietic agent, dipeptidyl-peptidase IV (CD26) inhibitor, fibroblast activation protein inhibitor
   Drugs Future29, 882-886.  I